Breast Cancer Core Needle Biopsy Market Report: Market Size & Forecast 2026

The breast cancer core needle biopsy market encompasses devices and technologies used to extract tissue samples from breast lesions for diagnostic evaluation. This procedure has become the standard of care for breast cancer diagnosis due to its accuracy, lower complication rates, and cost-effectiveness compared to surgical biopsies. Imaging guidance modalities such as ultrasound, mammography (stereotactic), and MRI are commonly employed to ensure precise needle placement during the procedure.

• •Market valued at approximately $0.85 billion in 2025 with consistent annual growth trajectory
• •Core needle biopsy represents the preferred initial diagnostic method for suspicious breast lesions globally
• •Procedures typically use automated or manual spring-loaded biopsy guns with 14-18 gauge needles

Rising global prevalence of breast cancer, with over 2.3 million new cases diagnosed annually worldwide, creates sustained demand for biopsy procedures. Increasing adoption of screening mammography programs leads to earlier detection of abnormalities requiring tissue sampling. Additionally, technological innovations in biopsy device design, including vacuum-assisted and co-axial techniques, improve diagnostic yield and patient comfort while reducing procedure time.

• •Growing elderly population and lifestyle factors contributing to increased breast cancer incidence rates
• •Shift from open surgical biopsy to minimally invasive needle-based procedures supported by clinical evidence
• •Expanding access to healthcare infrastructure in emerging markets driving procedural volume growth

The market is segmented by technology type, including automated biopsy devices, manual biopsy systems, and vacuum-assisted biopsy systems. End-use categories comprise hospitals, diagnostic imaging centers, and academic research institutions. Geographically, North America currently dominates market share due to advanced healthcare infrastructure and high screening compliance, while Asia-Pacific is projected to witness the fastest growth as healthcare spending increases.

• •Hospitals and diagnostic laboratories account for the largest share of procedure volumes globally
• •Automated core needle biopsy systems represent the fastest growing product segment
• •North America leads in market value, followed by Europe, with Asia-Pacific showing highest growth potential

What are the recent trends and outlook?

Integration of artificial intelligence and image-guided navigation systems is emerging as a key trend to enhance biopsy precision and reduce operator dependency. Increasing emphasis on personalized medicine drives demand for molecular analysis of biopsy samples, requiring higher quality tissue acquisition. The market is expected to maintain robust growth through 2035 as healthcare systems prioritize early-stage cancer detection and less invasive diagnostic approaches.

• •Rising adoption of MRI-guided and ultrasound-guided biopsy techniques for challenging lesions
• •Demand for co-axial biopsy systems increasing due to ability to obtain multiple samples through single entry point
• •Telemedicine and remote guidance technologies beginning to influence biopsy procedure delivery in rural areas